Compare NAZ & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAZ | SPRO |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 135.5M |
| IPO Year | 1995 | 2017 |
| Metric | NAZ | SPRO |
|---|---|---|
| Price | $12.80 | $2.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.6K | ★ 663.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $11.40 | $1.80 |
| 52 Week High | $13.00 | $3.09 |
| Indicator | NAZ | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 57.92 |
| Support Level | $11.72 | $2.18 |
| Resistance Level | $12.94 | $2.90 |
| Average True Range (ATR) | 0.16 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 57.88 | 64.08 |
Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.